Evidence map›Paper›PMID 27084511›Full record

ArticleBMC infectious diseases2016

Examining Plasmodium falciparum and P. vivax clearance subsequent to antimalarial drug treatment in the Myanmar-China border area based on quantitative real-time polymerase chain reaction.

Eugenia Lo, Jennifer Nguyen, Winny Oo, Elizabeth Hemming-Schroeder, Guofa Zhou, Zhaoqing Yang, Liwang Cui, Guiyun Yan

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Putative molecular markers ofFrontiers in epidemiology · 2024
    Article
  3. Pathogens (Basel, Switzerland) · 2021
    Article
  4. Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions.International journal for parasitology. Drugs and drug resistance · 2021
    Review
  5. Frontiers in pharmacology · 2021
    Review
  6. Genome-Wide Scans for GhanaianFrontiers in cellular and infection microbiology · 2021
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Eugenia LoProgram in Public Health, University of California at Irvine, Irvine, CA, 92697-4050, USA.
Jennifer NguyenProgram in Public Health, University of California at Irvine, Irvine, CA, 92697-4050, USA.
Winny OoProgram in Public Health, University of California at Irvine, Irvine, CA, 92697-4050, USA.
Elizabeth Hemming-SchroederProgram in Public Health, University of California at Irvine, Irvine, CA, 92697-4050, USA.
Guofa ZhouProgram in Public Health, University of California at Irvine, Irvine, CA, 92697-4050, USA.
Zhaoqing YangDepartment of Pathogen Biology and Immunology, Kunming Medical University, Kunming, China.
Liwang CuiDepartment of Entomology, Pennsylvania State University, University Park, PA, USA.
Guiyun YanProgram in Public Health, University of California at Irvine, Irvine, CA, 92697-4050, USA. guiyuny@uci.edu.
University of California, Irvine · USKunming Medical University · CNPennsylvania State University · US

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
NIAID NIH HHS U19 AI089672
6 · The paper itself

Abstract

backgroundRecent emergence of artemisinin-resistant P. falciparum has posed a serious hindrance to the elimination of malaria in the Greater Mekong Subregion. Parasite clearance time, a measure of change in peripheral parasitaemia in a sequence of samples taken after treatment, can be used to reflect the susceptibility of parasites or the efficiency of antimalarials. The association of genetic polymorphisms and artemisinin resistance has been documented. This study aims to examine clearance time of P. falciparum and P. vivax parasitemia as well as putative gene mutations associated with residual or recurred parasitemia in Myanmar.

methodsA total of 63 P. falciparum and 130 P. vivax samples collected from two internally-displaced populations and one surrounding village were examined for parasitemia changes. At least four samples were taken from each patient, at the first day of diagnosis up to 3 months following the initial treatment. The amount of parasite gene copy number was estimated using quantitative real-time PCR based on a species-specific region of the 18S rRNA gene. For samples that showed residual or recurred parasitemia after treatment, microsatellites were used to identify the 'post-treatment' parasite genotype and compared such with the 'pre-treatment' genotype. Mutations in genes pfcrt, pfmdr1, pfatp6, pfmrp1 and pfK13 that are potentially associated with ACT resistance were examined to identify if mutation is a factor for residual or persistent parasitemia.

resultsOver 30% of the P. falciprium infections showed delayed clearance of parasitemia after 2-3 days of treatment and 9.5% showed recurred parasitemia. Mutations in codon 876 of the pfmrp1 corroborated significance association with slow clearance time. However, no association was observed in the variation in pfmdr1 gene copy number as well as mutations of various codonsinpfatp6, pfcrt, and pfK13 with clearance time. For P. vivax, over 95% of the infections indicated cleared parasitemia at days 2-3 of treatment. Four samples were found to be re-infected with new parasite strains based on microsatellite genotypes after initial treatment.

conclusionThe appearance of P.falciparum infected samples showing delayed clearance or recurred parasitemia after treatment raises concerns on current treatment and ACT drug resistance.

Indexed as

AntimalarialsArtemisininsChinaDNA, ProtozoanDrug ResistanceGenotypeHumansMalaria, FalciparumMalaria, VivaxMicrosatellite RepeatsMyanmarPlasmodium falciparumPlasmodium vivaxProtozoan ProteinsReal-Time Polymerase Chain ReactionAntimalarialsartemisininArtemisininsDNA, ProtozoanProtozoan ProteinsArtemisinin-combined therapyMalariaMicrosatelliteParasite clearanceP. falciparumP. vivaxQuantitative PCRResistance genes

Identifiers

PMID27084511
PMCPMC4833920
OpenAlexW2340212454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.